Thermo Fisher and the new variant
Pinpointing new forms of the coronavirus could be vital, particularly if it mutates in response to vaccination, the company says.
US cuts fees for Covid-19 tests
Slower labs are to be paid less for Covid-19 tests, but will the move actually speed things up?
Exact gatecrashes the liquid biopsy party
Preliminary data on its pan-cancer blood test appear surprisingly competitive.
The Thermo-Qiagen saga comes to an end
Qiagen is one of the few medtechs to do well out of the Covid-19 pandemic. From Thermo Fisher’s point of view it has done too well.
A Covid-19 threat to business acquisitions
20 key healthcare transactions, most struck before the Covid-19 pandemic hit, have yet to be formally completed.
